FDA approves Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults – Axsome Therapeutics
Axsome Therapeutics, Inc. announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. Symbravo represents a novel… read more.
